Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: An opening study

Reproductive BioMedicine Online

Volumn 8, Issue 6, 2004, Pages 635-643

  Humaidan, Peter ^a   Bungum, M ^a   Bungum, L ^a   Andersen, C Yding ^b  

^a SKIVE REGIONAL HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

In vitro fertilization; Ovarian stimulation; Recombinant FSH; Recombinant LH

Indexed keywords

ANDROSTENEDIONE; BUSERELIN; CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN AGONIST; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG HALF LIFE; DRUG MECHANISM; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LUTEINIZING HORMONE BLOOD LEVEL; NIDATION; OVARY FUNCTION; OVULATION INDUCTION; PREGNANCY; RANDOMIZATION; SUPPLEMENTATION; TREATMENT OUTCOME;

EID: 2942519963     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61643-4     Document Type: Article

References (35)

1. Amsterdam A, Tajima K, Frajese V et al. 2002 Analysis of signal transduction stimulated by gonadotropins in granulosa cells. Molecular and Cellular Endocrinology 202, 77-80.
2. Balasch J, Miro F, Burzaco I et al. 1995 The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human FSH. Human Reproduction 10, 1678-1683.
3. Balasch J, Vidal E, Penarubia J et al. 2001 Suppression of LH during ovarian stimulation: analyzing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. Human Reproduction 16, 1636-1643.
4. Balasch J, Peñarrubia J, Fábregues et al. 2003 Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction. Reproductive BioMedicine Online 7, 35-42.
5. Chappel SC, Howles CM 1991 Re-evaluation of the roles of luteinizing hormone and follicle stimulating hormone in the ovulatory process. Human Reproduction 6, 1206-1212.
6. Daya S, Gunby J, Hughes EG et al. 1995 Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis. Fertility and Sterility 64, 347-354.
7. De Moustier B, Brinsden P, Bungum L et al. 2002 The effects of combined treatment of recombinant follicle stimulating hormone (r-hFSH) and recombinant luteinising hormone (r-hLH) in ratios from 1:1, 2:1, 3:1 in women aged between 38 and 42 years undergoing IVF-ICSI treatment. Human Reproduction 17, Abstract book 1. 18th ESHRE Annual Meeting, Abstract no O-158.
8. Esposito MA, Barnhart KT, Coutifaris C et al. 2001 Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone. Fertility and Sterility 75, 519-524.
9. European Recombinant Human LH Study Group 1998 Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH deficient anovulatory women: a dose-finding study. Journal of Clinical Endocrinology and Metabolism 83, 1507-1514.
10. Filicori M, Cognigni GE, Tabarrelli S et al. 1999 Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. Journal of Clinical Endocrinology and Metabolism 84, 2659-2663.
11. Filicori M, Cognigni CE, Tabarrelli S et al. 2001 Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. Journal of Clinical Endocrinology and Metabolism 86, 337-343.
12. Filicori M, Cognigni GE, Pocognoli P et al. 2003 Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle stimulating hormone. Fertility and Sterility 80, 390-397.
13. Fleming R, Chung CC, Yates RW et al. 1996 Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity. Human Reproduction 11, 1854-1858.
14. Fleming R, Lloyd F, Herbert M et al. 1998 Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Human Reproduction 13, 1788-1792.
15. Fleming R, Rehka P, Deshpande N et al. 2000 Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Human Reproduction 15, 1440-1445.
16. Hillier SG 1994 Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Human Reproduction 9, 188-191.
17. Humaidan P, Bungum L, Bungum M et al. 2002 Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Human Reproduction 17, 2016-2021.
18. Janssens RMJ, Lambalk CB, Wermeiden JPW et al. 2000 Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomised, double-blind, placebo-controlled study. Human Reproduction 15, 2333-2340.
19. Kelly EE, Nebiolo L 1999 Recombinant FSH therapy alone (Gonal-F) versus combination therapy (Gonal-F, r-hLH) in patients down regulated with low dose luteal GnRH agonist protocol. Preliminary results. 11th World Congress on In Vitro Fertilization and Human Reproductive Genetics. Abstract S-003.
20. Kilani Z, Dakkak A, Ghunaim S et al. 2003 A prospective, randomised, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Human Reproduction 18, 1194-1199.
21. Loumaye E, Engrand P, Howles CM et al. 1997 Assessment of the role of serum luteinizing hormone and estradiol response to follicle stimulating hormone on in vitro fertilization treatment outcome. Fertility and Sterility 67, 889-899.
22. Loumaye E, Engrand P, Shoham Z et al. 2003 Clinical evidence for an LH ceiling effect induced by administration of recombinant LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Human Reproduction 18, 314-322.
23. Piltonen T, Koivunen R, Ruokonen A et al. 2003 Ovarian age-related responsiveness to human chorionic gonadotropin. Journal of Clinical Endocrinology and Metabolism 88, 3327-3332.
24. Porchet HC, Le Cotonnec J-Y, Neuteboom, B et al. 1995 Pharmacokinetics of recombinant human luteinizing hormone after intravenous, intramuscular, and subcutaneous administration in monkeys and comparison with intravenous administration of pituitary human luteinizing hormone. Endocrinology 80, 667-673.
25. Rajaniemi HJ, Rönnberg L, Kauppila A 1980 Luteinizing hormone receptors in ovarian follicles of patients with polycystic ovarian disease. Journal of Clinical Endocrinology and Metabolism 51, 1054-1057.
26. Ranta T, Knecht M, Baukal AJ et al. 1984 GnRH agonist-induced inhibitory and stimulatory effects during ovarian follicular maturation. Molecular Cellular Endocrinology 35, 55-63.
27. Shoham Z 2002 The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertility and Sterility 77, 1170-1177.
28. Shoham Z, Balen A, Patel, A et al. 1991 Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients. Fertility and Sterility 56, 1048-1053.
29. Tesarik J, Mendoza C 2002 Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Human Reproduction 17, 3129-3137.
30. Tesarik J, Hazout A, Mendoza C 2003 Luteinizing hormone affects uterine receptivity independently of ovarian function. Reproductive BioMedicine Online 7, 59-64.
31. Vihko KK, Kujansuu E, Mörsky P et al. 1996 Gonadotropins and gonadotropin receptors during the perimenopause. European Journal of Endocrinology 134, 357-361.
32. Westergaard LG, Erb K, Laursen SB et al. 1996 The effect of human menopausal gonadotropin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotropic women. Human Reproduction 11, 1209-1213.
33. Westergaard LG, Laursen SB, Yding Andersen C 2000 Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in IVF treated normogonadotropic women. Human Reproduction 15, 1003-1008.
34. Westergaard LG, Erb K, Laursen SB et al. 2001 Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomised study. Human Reproduction 76, 543-549.
35. Zor U, Lamprecht SA, Misulovin Z et al. 1976 Refractoriness of ovarian adenylate cyclase to continued hormonal stimulation. Biochimica et Biophysica Acta 428, 761-765.